Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors
Objective. To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016. Our primary endpoint was time until need for levodopa among new monotherapy users of dopamine agonists and MAO-B inhibitors. M...
Saved in:
| Main Authors: | Caroline D. Binde, Ingunn F. Tvete, Marianne Klemp |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2021/9952743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dopamine agonists for restless legs syndrome
by: Pran Phakdeekitcharoen, et al.
Published: (2025-02-01) -
Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®)
by: M. R. Nodel
Published: (2011-09-01) -
Dopamine Partial Agonists in Pregnancy and Lactation: A Systematic Review
by: Alexia Koukopoulos, et al.
Published: (2025-07-01) -
Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
by: Edward Mignone, et al.
Published: (2025-01-01) -
Inhibition of levodopa metabolism to dopamine by honokiol short-chain fatty acid derivatives may enhance therapeutic efficacy in Parkinson’s disease
by: Gang Cheng, et al.
Published: (2025-06-01)